- Home
- 应用程序分析
- eMIMS Plus
- eMIMS Plus Vs. ARF RHD Guidelines
eMIMS Plus 对比 ARF RHD Guidelines 的使用情况和统计数据
Including much more information than the first eMIMS of 17 years ago, and with the ability to find it faster than ever, New eMIMS has been developed to meet the needs of our current users.
New eMIMS continues to be the trusted resource you know and love and remains your complete guide to Product Information, Consumer Medicine Information, Product Images, Drug Interactions and PBS restrictions and pricing for all registered medicines in Australia.
- Apple 应用商店
- 免费
- 医疗
商店排名
- -
Rheumatic heart disease represents the greatest cardiovascular inequality between Indigenous and non-Indigenous Australians. From 2013 to 2017, 94% of all new rheumatic heart disease cases were among Aboriginal and Torres Strait Islander people.
This app assists clinicians in the diagnosis and management of acute rheumatic fever and rheumatic heart disease. Published by RHDAustralia, based at Menzies School of Health Research, the app contains the most up-to-date evidence and details various aspects of patient care. It is informed by the 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (3rd edition), available at https://www.rhdaustralia.org.au/arf-rhd-guideline. The app also contains an ARF Diagnosis Calculator which embeds the lengthy and complex ARF diagnosis algorithms into a series of simple questions that assist clinicians to diagnose ARF. The algorithms comply with the 2015 American Heart Association revision of the Jones Criteria for diagnosis of ARF, which has been endorsed by the World Heart Federation, making the Diagnosis Calculator now able to be used globally.
- Apple 应用商店
- 免费
- 医疗
商店排名
- -
eMIMS Plus与ARF RHD Guidelines排名比较
对比 eMIMS Plus 与 ARF RHD Guidelines 在过去 28 天内的排名趋势
排名
没有可用的数据
eMIMS Plus 对比 ARF RHD Guidelines 的排名,按国家/地区比较
对比 eMIMS Plus 与 ARF RHD Guidelines 在过去 28 天内的排名趋势
所有品类
没有可用的数据
医疗
通过免费试用版比较任何网站
eMIMS Plus VS.
ARF RHD Guidelines
十二月 12, 2024